Evidence map›Paper›PMID 39592630›Full record

ArticleNature communications2024

Spatially organized tumor-stroma boundary determines the efficacy of immunotherapy in colorectal cancer patients.

Yu Feng, Wenjuan Ma, Yupeng Zang, Yanying Guo, Young Li, Yixuan Zhang, Xuan Dong, Yi Liu, Xiaojuan Zhan, Zhizhong Pan and 8 more

Abstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Yu Feng *Shanxi Medical University-BGI Collaborative Center for Future Medicine, Shanxi Medical University, Taiyuan, 030001, China.
Wenjuan Ma *State Key Laboratory of Oncology in South China, Guangzhou, 510060, Guangdong, People's Republic of China.
Yupeng ZangCollege of Life Sciences, University of Chinese Academy of Sciences, 100049, Beijing, China.ORCID 0000-0002-5098-1172
Yanying GuoBGI Research, Shenzhen, 519083, China.
Young LiBGI Research, Shenzhen, 519083, China.
Yixuan ZhangSchool of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong SAR, 999077, China.
Xuan DongBGI Research, Hangzhou, 310030, China.ORCID 0000-0001-8288-322X
Yi LiuBGI Research, Hangzhou, 310030, China.
Xiaojuan ZhanBGI Research, Shenzhen, 519083, China.
Zhizhong PanState Key Laboratory of Oncology in South China, Guangzhou, 510060, Guangdong, People's Republic of China.
Mei LuoBGI Research, Hangzhou, 310030, China.
Miaoqing WuState Key Laboratory of Oncology in South China, Guangzhou, 510060, Guangdong, People's Republic of China.
Ao ChenBGI Research, Shenzhen, 519083, China.ORCID 0000-0002-9699-8340
Da KangState Key Laboratory of Oncology in South China, Guangzhou, 510060, Guangdong, People's Republic of China.
Gong ChenState Key Laboratory of Oncology in South China, Guangzhou, 510060, Guangdong, People's Republic of China. chengong@sysucc.org.cn.
Longqi LiuShanxi Medical University-BGI Collaborative Center for Future Medicine, Shanxi Medical University, Taiyuan, 030001, China. liulongqi@genomics.cn.ORCID 0000-0002-5828-5542
Jingying ZhouSchool of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong SAR, 999077, China. zhoujy@cuhk.edu.hk.ORCID 0000-0002-9740-6159
Rongxin ZhangState Key Laboratory of Oncology in South China, Guangzhou, 510060, Guangdong, People's Republic of China. zhangrx@sysucc.org.cn.ORCID 0000-0001-5498-0428

Funding

Chinese Society of Clinical Oncology (Chinese Society of Clinical Oncology, Beijing Xisike Clinical Oncology Research Foundation) Y-HR2018-319Chinese Society of Clinical Oncology (Chinese Society of Clinical Oncology, Beijing Xisike Clinical Oncology Research Foundation) Y-JS2019-009Chinese Society of Clinical Oncology (Chinese Society of Clinical Oncology, Beijing Xisike Clinical Oncology Research Foundation) Y-L2017-002National Natural Science Foundation of China (National Science Foundation of China) 82473398
6 · The paper itself

Abstract

Colorectal cancer (CRC) patients with mismatch repair (MMR)-deficient (dMMR) but not MMR-proficient (pMMR) tend to benefit from immune checkpoint blockade (ICB) therapy. To profile the tumor microenvironments (TME) underlying these varied therapeutic responses, we integrate spatial enhanced resolution omics-sequencing (Stereo-seq), single-cell RNA sequencing, and multiplexed imaging analysis to create high-definition spatial maps of tumors from treatment-naïve and ICB-treated CRC patients. Our results identify the spatial organization and immune status of the tumor-stroma boundary as a distinctive feature of dMMR and pMMR CRCs, which associates with ICB response. The physical interactions and abundance of LAMP3

Indexed as

Colorectal NeoplasmsImmune Checkpoint InhibitorsImmunotherapyTumor MicroenvironmentCancer-Associated FibroblastsDNA Mismatch RepairFemaleHumansMaleSingle-Cell AnalysisStromal CellsImmune Checkpoint Inhibitors

Identifiers

PMID39592630
PMCPMC11599708

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.